Zug, Switzerland, November 22, 2016 – Swiss pharmaceutical company Primex Pharmaceuticals AG announces acquisition of OGNA. The acquisition expands the company’s product portfolio to the full dental surgery range, from local anaesthetics to dental products.
OGNA manufactures and commercializes solutions for dental surgery needs, e.g. local anaesthetics, root canal irrigation and cementation, detergents and disinfectants. Constant search for innovative solutions within the dental market and the determination to guarantee excellence to customers has led OGNA to become a leader in Italy, and it is the first and sole full range dental products manufacturer in the country. Italy is the world’s third largest producer of dental supplies.
OGNA is a 100-year-old family company founded by Giovanni Ogna in Milan. In 1960, the company obtained the desired certification from the FDA to produce generic drugs in the USA. Today, OGNA has a full range of dental products and pharmaceuticals.
Primex is integrating the former OGNA companies into the Group and reorganizing its commercial functions under the original company name “Giovanni Ogna et Figli S.r.l.”, which is now a wholly-owned subsidiary of Primex Pharmaceuticals AG.
Kari Sarvanto, CEO and Co-Founder of Primex Group, comments: “With the acquisition, Primex gets not only new anaesthesia products that can be equally applied for non-dental use, but also acquires a key distribution network. Via OGNA’s global expansion, this is especially potential for the novel procedural sedative we expect to launch soon.”
For further information, please contact:
Primex Pharmaceuticals AG Mr. Kari Sarvanto, Group CEO Mobile: +41 796 162 694 Email: firstname.lastname@example.org
About Primex Pharmaceuticals
Primex Pharmaceuticals is a fast-growing global specialty pharma company spearheading a new lean pharmaceutical business model.
Primex aims to become the leading global innovative anaesthesia company, helping patients undergo a wide range of medical procedures, and to expand in pediatrics and orphan pharmaceuticals. With a portfolio of strong, trusted anaesthesia products from propofol-based products acquired from Bayer to the recent novel oral solution for pediatric anaesthesiology and procedural sedation, Primex will continue to identify and acquire new medications that complete the ‘Triad of Anaesthesia’.
Primex Pharmaceuticals’ global partner network operates in over 40 countries and reaches a population of one billion. The company is headquartered in Zug, Switzerland; all Primex products are manufactured in the EU or Switzerland. Primex has proven underlying business operations and historically strong revenue growth.